Naurex has developed 2nd- and 3rd-generation compounds that modulate the NMDA receptor with a wide variety of partial agonist/antagonist activity profiles. These molecules include a structurally distinct series of orally available small molecules.
These compounds represent the first outputs of Naurex's proprietary NMDAR modulation platform, comprising novel patented chemistry classes with key molecular features. The molecules from this platform have diverse activity profiles with high potential as therapies for a variety of CNS disorders.
The lead molecule from Naurex's 2nd-generation series of compounds is NRX-1074. Preclinical studies of NRX-1074 have
shown that it:
- Is orally bioavailable.
- Has an in vivo mechanistic signature similar to GLYX-13 with a ketamine-like efficacy signature, including:
- Rapid onset of antidepressant-like effect, and
- Long-acting duration of effect.
- Demonstrates no signs of CNS-related side effects.
Naurex’s initial development focus for this fast-acting, potent, orally available compound is in major depression. Naurex expects to file an Investigational New Drug (IND) application for NRX-1074 in early 2013.
Naurex has also identified potential lead molecules from its 3rd-generation series of compounds. These compounds have a different activity profile from the antidepressant compounds and are potentially well-suited to the treatment of schizophrenia, including negative and cognitive symptoms of the disorder. These 3rd-generation molecules are currently in preclinical development.
Naurex is also advancing a number of additional compounds from its 2nd- and 3rd-generation series into preclinical development. These compounds have demonstrated high potential as therapies for various CNS disorders.